JP2023546054A5 - - Google Patents
Info
- Publication number
- JP2023546054A5 JP2023546054A5 JP2023522409A JP2023522409A JP2023546054A5 JP 2023546054 A5 JP2023546054 A5 JP 2023546054A5 JP 2023522409 A JP2023522409 A JP 2023522409A JP 2023522409 A JP2023522409 A JP 2023522409A JP 2023546054 A5 JP2023546054 A5 JP 2023546054A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- ring
- substituted
- cases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/120605 | 2020-10-13 | ||
| CN2020120605 | 2020-10-13 | ||
| CN2021118149 | 2021-09-14 | ||
| CNPCT/CN2021/118149 | 2021-09-14 | ||
| PCT/CN2021/123515 WO2022078380A1 (en) | 2020-10-13 | 2021-10-13 | Heterocyclic glp-1 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546054A JP2023546054A (ja) | 2023-11-01 |
| JP2023546054A5 true JP2023546054A5 (https=) | 2025-01-07 |
Family
ID=81207669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023522409A Pending JP2023546054A (ja) | 2020-10-13 | 2021-10-13 | ヘテロ環ｇｌｐ－１アゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240083886A1 (https=) |
| EP (1) | EP4229049A4 (https=) |
| JP (1) | JP2023546054A (https=) |
| CN (1) | CN116547278A (https=) |
| WO (1) | WO2022078380A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206429A (zh) | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| JP2023537501A (ja) | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| EP4204415A4 (en) | 2020-08-28 | 2025-03-26 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| CA3188891A1 (en) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2023029380A1 (zh) | 2021-08-30 | 2023-03-09 | 杭州德睿智药科技有限公司 | 作为glp1r激动剂的新型芳醚取代杂环类化合物 |
| US20240374587A1 (en) | 2021-09-08 | 2024-11-14 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| MX2024004131A (es) | 2021-10-05 | 2024-04-22 | Astrazeneca Ab | Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1. |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| EP4562006A1 (en) * | 2022-07-27 | 2025-06-04 | Carmot Therapeutics, Inc. | N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| KR20250085816A (ko) | 2022-11-16 | 2025-06-12 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090130345A (ko) * | 2007-05-04 | 2009-12-22 | 아이알엠 엘엘씨 | Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 화합물 및 조성물 |
| EP3225618B1 (en) * | 2014-11-26 | 2020-05-06 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| DK3806855T5 (da) * | 2018-06-15 | 2023-05-22 | Pfizer | GLP-1-receptoragonister og anvendelser deraf |
| MA54555A (fr) * | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| WO2021096284A1 (ko) * | 2019-11-15 | 2021-05-20 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
-
2021
- 2021-10-13 US US18/248,858 patent/US20240083886A1/en active Pending
- 2021-10-13 EP EP21879423.8A patent/EP4229049A4/en active Pending
- 2021-10-13 CN CN202180082168.XA patent/CN116547278A/zh active Pending
- 2021-10-13 JP JP2023522409A patent/JP2023546054A/ja active Pending
- 2021-10-13 WO PCT/CN2021/123515 patent/WO2022078380A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023546054A5 (https=) | ||
| JP2023546055A5 (https=) | ||
| JP2023537501A5 (https=) | ||
| JP2023524493A5 (https=) | ||
| JP2023515404A5 (https=) | ||
| JP2023538949A5 (https=) | ||
| JP2023513272A5 (https=) | ||
| US20230201185A1 (en) | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| JP2023540558A5 (https=) | ||
| RU2345067C2 (ru) | Ингибиторы дпп-iv | |
| JP2023540609A5 (https=) | ||
| JP2025506473A5 (https=) | ||
| US9382229B2 (en) | Compounds and methods of use thereof for treating neurodegenerative disorders | |
| US20240294525A1 (en) | Compounds as glp-1 receptor agonists and uses thereof | |
| JP7769695B2 (ja) | Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用 | |
| US20170088532A1 (en) | Inhibitors of lpxc | |
| US20130023522A1 (en) | Benzamides | |
| CA2889697C (en) | Cannabinoid receptor mediating compounds | |
| CA2657350A1 (en) | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | |
| US9238074B2 (en) | Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid | |
| JP2009501776A (ja) | 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用 | |
| JP2010504321A5 (https=) | ||
| TW201418250A (zh) | 含有雜環的５－羥基吲哚類衍生物及其用途 | |
| CN117337281A (zh) | 作为可溶性环氧化物水解酶抑制剂的哌啶脲衍生物 | |
| JP3410476B2 (ja) | 新規なエポキシコハク酸アミド誘導体又はその塩 |